The primary objective of this noninterventional study is to compare the proportion of patients with moderate-to-severe plaque psoriasis treated in clinical practice with ixekizumab or secukinumab (the anti-IL-17A cohort) relative to other biologic treatments who achieve clear or almost clear skin equivalent to psoriasis area and severity index (PASI) 90 or higher and/or static Physician Global Assessment (sPGA) 0/1 at 12±4 weeks following initiation of or switching to a new biologic.